Targeting CDK4 (cyclin-dependent kinase) amplification in liposarcoma: A comprehensive review

Tarek Assi; Joseph Kattan; Elie Rassy; Hussein Nassereddine; Fadi Farhat; Charles Honore; Axel Le Cesne; Julien Adam; Olivier Mir

doi:10.1016/j.critrevonc.2020.103029

Targeting CDK4 (cyclin-dependent kinase) amplification in liposarcoma: A comprehensive review

Tarek Assi, Joseph Kattan, Elie Rassy, Hussein Nassereddine, Fadi Farhat, Charles Honore, Axel Le Cesne, Julien Adam, Olivier Mir

Résultats de recherche: Contribution à un journal › Article 'review' › Revue par des pairs

41 Citations (Scopus)

Résumé

Well-differentiated/dedifferentiated (WD/DD) liposarcomas, the most common form of liposarcomas, constitute up to 20 % of all soft tissue sarcomas. Several oncogenes are thought to be involved in liposarcoma pathogenesis, mainly MDM2, CDK4 and HMGA2. While MDM2 inhibitors are now tested in clinical trials, a second actionable and promising target appears to be cyclin-dependent kinase 4 (CDK4), which is amplified in up to 90 % of well differentiated or dedifferentiated (WD/DD) liposarcoma. With the paucity of available therapeutic options, the inhibition of CDK4 represent a potential therapeutic option. In this paper, we review the role of CDK4/6 inhibitors in targeting the commonly identified CDK4 amplification in WD/DD liposarcoma, with an emphasis on the published and currently ongoing trials.

langue originale	Anglais
Numéro d'article	103029
journal	Critical Reviews in Oncology/Hematology
Volume	153
Les DOIs	https://doi.org/10.1016/j.critrevonc.2020.103029
état	Publié - 1 sept. 2020

Accès au document

10.1016/j.critrevonc.2020.103029

Autres fichiers et liens

Lien vers la publication dans Scopus

Contient cette citation

@article{04687cbc82fb4de4b2ba28f5358d6128,

title = "Targeting CDK4 (cyclin-dependent kinase) amplification in liposarcoma: A comprehensive review",

abstract = "Well-differentiated/dedifferentiated (WD/DD) liposarcomas, the most common form of liposarcomas, constitute up to 20 % of all soft tissue sarcomas. Several oncogenes are thought to be involved in liposarcoma pathogenesis, mainly MDM2, CDK4 and HMGA2. While MDM2 inhibitors are now tested in clinical trials, a second actionable and promising target appears to be cyclin-dependent kinase 4 (CDK4), which is amplified in up to 90 % of well differentiated or dedifferentiated (WD/DD) liposarcoma. With the paucity of available therapeutic options, the inhibition of CDK4 represent a potential therapeutic option. In this paper, we review the role of CDK4/6 inhibitors in targeting the commonly identified CDK4 amplification in WD/DD liposarcoma, with an emphasis on the published and currently ongoing trials.",

keywords = "Abemaciclib, CDK4, Liposarcoma, MDM2, Palbociclib, Ribociclib, Soft tissue sarcoma",

author = "Tarek Assi and Joseph Kattan and Elie Rassy and Hussein Nassereddine and Fadi Farhat and Charles Honore and {Le Cesne}, Axel and Julien Adam and Olivier Mir",

note = "Publisher Copyright: {\textcopyright} 2020 Elsevier B.V.",

year = "2020",

month = sep,

day = "1",

doi = "10.1016/j.critrevonc.2020.103029",

language = "English",

volume = "153",

journal = "Critical Reviews in Oncology/Hematology",

issn = "1040-8428",

}

TY - JOUR

T1 - Targeting CDK4 (cyclin-dependent kinase) amplification in liposarcoma

T2 - A comprehensive review

AU - Assi, Tarek

AU - Kattan, Joseph

AU - Rassy, Elie

AU - Nassereddine, Hussein

AU - Farhat, Fadi

AU - Honore, Charles

AU - Le Cesne, Axel

AU - Adam, Julien

AU - Mir, Olivier

PY - 2020/9/1

Y1 - 2020/9/1

N2 - Well-differentiated/dedifferentiated (WD/DD) liposarcomas, the most common form of liposarcomas, constitute up to 20 % of all soft tissue sarcomas. Several oncogenes are thought to be involved in liposarcoma pathogenesis, mainly MDM2, CDK4 and HMGA2. While MDM2 inhibitors are now tested in clinical trials, a second actionable and promising target appears to be cyclin-dependent kinase 4 (CDK4), which is amplified in up to 90 % of well differentiated or dedifferentiated (WD/DD) liposarcoma. With the paucity of available therapeutic options, the inhibition of CDK4 represent a potential therapeutic option. In this paper, we review the role of CDK4/6 inhibitors in targeting the commonly identified CDK4 amplification in WD/DD liposarcoma, with an emphasis on the published and currently ongoing trials.

AB - Well-differentiated/dedifferentiated (WD/DD) liposarcomas, the most common form of liposarcomas, constitute up to 20 % of all soft tissue sarcomas. Several oncogenes are thought to be involved in liposarcoma pathogenesis, mainly MDM2, CDK4 and HMGA2. While MDM2 inhibitors are now tested in clinical trials, a second actionable and promising target appears to be cyclin-dependent kinase 4 (CDK4), which is amplified in up to 90 % of well differentiated or dedifferentiated (WD/DD) liposarcoma. With the paucity of available therapeutic options, the inhibition of CDK4 represent a potential therapeutic option. In this paper, we review the role of CDK4/6 inhibitors in targeting the commonly identified CDK4 amplification in WD/DD liposarcoma, with an emphasis on the published and currently ongoing trials.

KW - Abemaciclib

KW - CDK4

KW - Liposarcoma

KW - MDM2

KW - Palbociclib

KW - Ribociclib

KW - Soft tissue sarcoma

UR - http://www.scopus.com/inward/record.url?scp=85086788781&partnerID=8YFLogxK

U2 - 10.1016/j.critrevonc.2020.103029

DO - 10.1016/j.critrevonc.2020.103029

M3 - Review article

C2 - 32593094

AN - SCOPUS:85086788781

SN - 1040-8428

VL - 153

JO - Critical Reviews in Oncology/Hematology

JF - Critical Reviews in Oncology/Hematology

M1 - 103029

ER -